Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis.
Overview
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University,Chicago, IL USA
- Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,Chicago, IL USA
Abstract
Cell-based therapies can formulate and deliver biologics within the brain, but their development has relied largely on survival outcomes that do not distinguish inadequate payload potency from inadequate tumor distribution. We evaluated intratumoral coverage as a quantitative endpoint for cell-mediated delivery using neural stem cells (NSCs) engineered to secrete an anti-HER2 antibody in breast cancer brain metastasis. Intracranial HER2-positive BT474Br tumors received a single dose of 5 × 105 anti-HER2 antibody-secreting NSCs. Secreted human IgG was reconstructed across consecutive 10-µm sections spanning the entire tumor depth, and therapeutic activity of the same cell dose administered once was assessed in an independent survival experiment. A single NSC dose produced a mean section-level antibody coverage of 60.6%; coverage was ≥ 25% in 96.8% of sections and ≥ 50% in 74.2%. Coverage was greatest in the tumor core and declined toward both poles, a pattern consistent with carrier-cell localization limiting therapeutic reach. The same dose extended median survival from 67 days with vector-control NSCs to 73.5 days (P = 0.0009) and increased restricted mean survival by 10.8 days. These data provide an initial spatial benchmark for a therapeutically active dose and establish tumor coverage as a mechanistically informative endpoint for intracranial cell-based delivery.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Data availability
The data generated in this study are available within the article. Analysis code used for the survival and spatial statistics is available upon reasonable request.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 12 November 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 8 authors, 6 keywords, 10 MeSH terms, 1 funder, 57 references.
Cite
This paper
Fares, J., Kanojia, D., Petrosyan, E., Tobias, A. L., Chojak, R., Ahmed, A. U., Balyasnikova, I. V., & Lesniak, M. S. (2026). Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis. Clinical & experimental metastasis, 43(6), 64. https://
BibTeX
@article{fares2026mappin
author = {Fares, Jawad and Kanojia, Deepak and Petrosyan, Edgar and Tobias, Alex L. and Chojak, Rafal and Ahmed, Atique U. and Balyasnikova, Irina V. and Lesniak, Maciej S.},
title = {{Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis}},
journal = {Clinical \& experimental metastasis},
year = {2026},
month = nov,
volume = {43},
number = {6},
pages = {64},
publisher = {Springer Science+Business Media},
issn = {0262-0898},
doi = {10.1007/
url = {https://
pmid = {43007545},
pmcid = {PMC13751723}
}
RIS
TY - JOUR
AU - Fares, Jawad
AU - Kanojia, Deepak
AU - Petrosyan, Edgar
AU - Tobias, Alex L.
AU - Chojak, Rafal
AU - Ahmed, Atique U.
AU - Balyasnikova, Irina V.
AU - Lesniak, Maciej S.
TI - Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis
T2 - Clinical & experimental metastasis
J2 - Clin Exp Metastasis
PY - 2026
DA - 2026/
VL - 43
IS - 6
SP - 64
SN - 0262-0898
PB - Springer Science+Business Media
DO - 10.1007/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1007/
"type": "article-journal",
"title": "Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis",
"container-title": "Clinical & experimental metastasis",
"author": [
{
"family": "Fares",
"given": "Jawad"
},
{
"family": "Kanojia",
"given": "Deepak"
},
{
"family": "Petrosyan",
"given": "Edgar"
},
{
"family": "Tobias",
"given": "Alex L."
},
{
"family": "Chojak",
"given": "Rafal"
},
{
"family": "Ahmed",
"given": "Atique U."
},
{
"family": "Balyasnikova",
"given": "Irina V."
},
{
"family": "Lesniak",
"given": "Maciej S."
}
],
"container-title-short":
"volume": "43",
"issue": "6",
"page": "64",
"DOI": "10.1007/
"PMID": "43007545",
"PMCID": "PMC13751723",
"ISSN": "0262-0898",
"publisher": "Springer Science+Business Media",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
11,
10
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1080/14796694.2025.2470604
- TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.Journal: Future oncology (London, England)In common: other condition, 6 references
- [2] doi:10.1159/000552141
- Long-Term Complete Radiological Response in a Patient with Brain Metastases from HER2-Positive Breast Cancer Treated with Trastuzumab Deruxtecan: A Case Report and Literature Review.Journal: Case reports in oncologyIn common: other condition, 4 references
- [3] doi:10.1038/s41467-023-36878-2 [code]
- Checkpoint kinase 1/
2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Journal: Nature communicationsIn common: other condition, mouse, author Jawad Fares - [4] doi:10.1126/sciadv.adn1607
- Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone.Journal: Science advancesIn common: other condition, mouse, 3 references
- [5] doi:10.1093/neuonc/noaf106
- Dual aVß8 Integrin and PD-1 Blockade Overcomes TGFβ-Mediated B-Cell Suppression to Enhance Anti-Tumor Immunity.Journal: Neuro-oncologyIn common: other condition, mouse, author Maciej S. Lesniak
- [6] doi:10.1172/jci177384
- B cell-based therapy produces antibodies that inhibit glioblastoma growth.Journal: The Journal of clinical investigationIn common: other condition, mouse, author Maciej S. Lesniak
- [7] doi:10.1038/s41467-023-37328-9
- STING agonist-loaded, CD47/
PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Journal: Nature communicationsIn common: other condition, mouse, author Maciej S. Lesniak - [8] doi:10.1158/2767-9764.crc-25-0639 [code]
- Interleukin-34-Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis.Journal: Cancer research communicationsIn common: other condition, mouse, 3 references
- [9] doi:10.1002/btm2.10406
- Gene therapy using genome-edited iPS cells for targeting malignant glioma.Journal: Bioengineering & translational medicineIn common: other condition, 3 references
- [10] doi:10.1016/j.omton.2026.201201
- Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.Journal: Molecular therapy. OncologyIn common: other condition, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.